Cargando…
Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero‐Test bile string
Daprodustat is an oral small molecule hypoxia‐inducible factor (HIF) prolyl hydroxylase inhibitor (PHI) approved in Japan and the United States for the treatment of anemia associated with chronic kidney disease. This phase 1, nonrandomized, 2‐period, crossover study in 6 healthy men characterized an...
Autores principales: | Tai, Guoying, Xia, Fangming, Chen, Cathy, Pereira, Adrian, Pirhalla, Jill, Miao, Xiusheng, Young, Graeme, Beaumont, Claire, Chen, Liangfu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603292/ https://www.ncbi.nlm.nih.gov/pubmed/37885335 http://dx.doi.org/10.1002/prp2.1145 |
Ejemplares similares
-
Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination
por: Mahar, Kelly M., et al.
Publicado: (2021) -
Daprodustat: First Approval
por: Dhillon, Sohita
Publicado: (2020) -
An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects
por: Cizman, Borut, et al.
Publicado: (2018) -
Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients
por: Kanai, Hidetoshi, et al.
Publicado: (2021) -
Opportunities in low-level radiocarbon microtracing: applications and new technology
por: Vuong, Le Thuy, et al.
Publicado: (2015)